Selectively Oncolytic Mutant of HSV-1 Lyses HeLa Cells Mediated by Ras/RTN3

Yue Su, Huabin Zhu, Wei Xiao, Qin Xu, Lei Zhu, Xianrong Zhang, Qinwen Wan, Shumin Zhou, Enqi Du, Hua Xu, Lunguang Yao, Songya Lv, Baoli Hu, Yingle Liu and Yipeng Qi

volume 6 | issue 2

February 2007
Pages: 202 - 208

We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:

Download PDF

If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.

The selectively oncolytic mtHSV, a HSV icp34.5 mutant with lacz gene insertion, was proved that it was targeted for treating tumors but not other organs, however, its oncolytic mechanism is under confirmation. The results showed that HeLa cells could be lysed efficiently by mtHSV in vitro. In the flow cytometry and Western blot experiment, Ras protein was obviously down-regulated on plasma membrane (PM) while the whole Ras protein didn’t change along with up-regulation of reticulon 3(RTN3) protein at 48h post infection of mtHSV in HeLa cells . Expression of Ras protein on PM and whole Ras protein in HeLa cells was down-regulated by siFTa（inhibitor ofαsubunits of human farnesyltransferase with siRNA）and siRTN3(inhibitor of RTN3 with siRNA) respectively, and HeLa cells could be killed effectively by siFTa and siRTN3 at 48h post transfection. So siFTa and siRTN3 effectively suppressed mtHSV infection of HeLa cells. Further, experiments were made to study the relationship between Ras and RTN3 using confocal colocalization and co-immunoprecipitation. The results exhibited that Ras could interact with RTN3 at endoplasmic reticulum. The data put forward that Ras/RTN3 is an important access to HeLa cells for mtHSV. The molecular interaction between Ras and RTN3 may further improve the understanding of the function of Ras and RTN3 in mtHSV infection. The results provide further theoretical evidence that mtHSV may be used as an oncolytic agent for cancer therapy.